Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke. - Wikidata - awgldk - TriplyDB

Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.

Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.

http://www.wikidata.org/entity/Q35996183

about

Sulfonylurea receptor 1 in central nervous system injury: a focused review Disruption of ion homeostasis in the neurogliovascular unit underlies the pathogenesis of ischemic cerebral edema Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia MRI evidence that glibenclamide reduces acute lesion expansion in a rat model of spinal cord injury.Effect of glibenclamide on the prevention of secondary brain injury following ischemic stroke in humans.Glibenclamide for the treatment of ischemic and hemorrhagic stroke.Exploratory analysis of glyburide as a novel therapy for preventing brain swelling.Heterogeneity of aquaporin-4 localization and expression after focal cerebral ischemia underlies differences in white versus grey matter swelling SUR1-Associated Mechanisms Are Not Involved in Ischemic Optic Neuropathy 1 Day Post-Injury.Sur1-Trpm4 Cation Channel Expression in Human Cerebral Infarcts A Direct Comparison of Three Clinically Relevant Treatments in a Rat Model of Cervical Spinal Cord Injury.Does inhibiting Sur1 complement rt-PA in cerebral ischemia?Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas.The protective effect of glibenclamide in a model of hemorrhagic encephalopathy of prematurity.Intravenous infusion of magnesium chloride improves epicenter blood flow during the acute stage of contusive spinal cord injury in rats.The Sur1-Trpm4 channel regulates NOS2 transcription in TLR4-activated microglia.Sulfonylurea receptor 1 expression in human cerebral infarcts.Glibenclamide Is Comparable to Target Temperature Management in Improving Survival and Neurological Outcome After Asphyxial Cardiac Arrest in Rats.Glibenclamide for the treatment of acute CNS injury.Glibenclamide in cerebral ischemia and stroke Clinical predictors and management of hemorrhagic transformation.Pathogenesis of brain edema and investigation into anti-edema drugs.Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design.α-Endosulfine (ARPP-19e) Expression in a Rat Model of Stroke.GABA transmission via ATP-dependent K+ channels regulates α-synuclein secretion in mouse striatum.Implantable systems for drug delivery to the brain.Role of Glibenclamide in Brain Injury After Intracerebral Hemorrhage.SUR1-TRPM4 channel activation and phasic secretion of MMP-9 induced by tPA in brain endothelial cells.Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date

P2860

Q24606564-22FA142A-A720-4A1A-82E5-97362D66BC4B Q26825616-30033528-2EAB-48F4-A48A-A099F81C965C Q28575299-D63A6130-A4A9-4570-AB86-2209B93524EF Q29144159-0FD4AE95-015E-4615-9408-6364D093DAE7 Q33825191-835511DD-E753-44C4-ABC8-77D827F4CE47 Q34522397-3DEB9A02-0A0F-4D41-AAB0-9ACE25214AC5 Q35380697-57CAB462-3431-45FD-9E28-AF267EC6A226 Q35619128-A05C0B52-FE03-4438-B644-D53AFDFB31EF Q36106107-1F75DE61-1D86-4CAC-AC3C-29CF20F80855 Q36112858-962CF7D0-2FD6-4A39-B844-4182EE3471AB Q36204722-030F5074-3C33-4BAE-A57F-04A6A8062D3A Q36263581-F374963E-9FBF-4F10-B4E9-60B3A205A2F3 Q36426567-C343FE14-2EC9-4418-9D36-C4DE5F84D9F5 Q36515347-82EA3B4A-8C5C-4110-B375-D1224EC51186 Q36825406-96A39B7C-3E28-4BE1-A164-6A221A1487E3 Q36862969-B141A864-4073-4F0C-9D22-6079D26CC1B1 Q36955393-5F74196A-0B9F-45DD-AF59-0C3AE986DF68 Q37167025-A20BC596-F8BE-4E3F-8991-E7B675DF13F5 Q37240684-DBCA79AF-2D07-477E-811C-DE16FC790BD7 Q37279993-BEF8AC1D-B770-4DB1-B06D-1317B371CDDF Q37638478-B0C0B0C3-2198-42C6-B6C2-A0AC79F6A85E Q38074569-278AC193-FEDF-40B7-84CD-1473A1FED554 Q38459572-298236D1-50EC-4033-8B7E-9BA2ED30C5E7 Q38974854-BCE1B154-7595-4C74-893D-40CBB90B18B1 Q46304933-308F443A-15BF-4EE5-A3E2-40DDA2452459 Q46590384-01D8D5C0-5218-4BD4-A223-48CE79054052 Q47975817-77DDF1D4-C8D8-4A3C-B6DD-2E78CCE8151E Q48444155-87D403AF-D2F0-49F1-97CD-BE7823F83230 Q55116313-3751324B-52D5-46C8-BC07-EF1174D4E501 Q58777731-313AE00C-7E22-4F57-B552-366B0D5CB919

P2860

Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.

http://www.wikidata.org/entity/Q35996183

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.

@ast

Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.

@en

type

label

Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.

@ast

Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.

@en

prefLabel

Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.

@ast

Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.

@en

P1433

Q35996183-939FECFA-47F0-4FBA-8C27-7C6F9DF2D435

P1476

Q35996183-3E7D21F3-D436-4E1C-9A7F-3D762EEC9AC0

P2093

Q35996183-38D53FC9-E4B0-43FB-B3FE-FD93FB0CDA27

Q35996183-60233B43-AD4D-450B-A89D-EBCE9ABD67BF

Q35996183-8DF0BA58-7C35-466E-B398-73514A5F1571

Q35996183-9D33292C-2812-4DB9-8CE1-66C0793FE206

Q35996183-A2321AF7-6526-4767-81A0-82BDC0765235

Q35996183-DE7B4045-B404-4B7F-B9E6-C283D1E70F4F

Q35996183-EE595DBC-7AEE-4578-9F24-CAE3BE68CDE1

Q35996183-FA037011-A280-43C4-B26D-B53A02B27F0D

P2860

Q35996183-08254266-5C5E-4925-BE9E-96C67464EC61

Q35996183-0D9526B4-2B91-4871-BFF7-0E1261F2351F

Q35996183-1EC89886-F98D-4B44-991B-4F1E9B7479C3

Q35996183-2055BA3F-03FE-415C-9B06-BBE97624A564

Q35996183-26D89D32-9810-4510-AB4D-4232E4E63C3D

Q35996183-305CC72E-6B9B-4BD2-B130-010D3B098B58

Q35996183-32BB828A-8420-4EF0-BC28-B6FC262F48EE

Q35996183-3EF4D70C-2C88-4D6D-B265-53CBCA129E1B

Q35996183-533A90B7-4D65-4A1C-8601-B526086BC9CB

Q35996183-5ED24FDB-0EFC-4564-968D-BC14F834F20A

P2888

Q35996183-C9EC2E67-616B-4C0F-A16A-FDE1B94ED276

P304

Q35996183-4BFFDDD1-9F4E-4804-9DB7-85AEA6072DBF

P31

Q35996183-7F6FA8E2-5FCA-40D0-B2AC-B2E4C4DF65D9

P356

Q35996183-38604DB5-E4BF-4CB0-B510-916A4F19B812

P433

Q35996183-CD2483BA-F1BC-46EA-A89B-25A68CE1CDCB

P478

Q35996183-AE9AACC5-F81D-428C-891D-C4BDC1CBEED1

P577

Q35996183-7D853073-A3F0-44DC-A33A-93881A0EE49C

P5875

Q35996183-8614D98E-464B-4101-AD7F-E69E90C603BE

P698

Q35996183-527C86FC-C995-42B4-8E42-A211BE9EEC5F

P932

Q35996183-80DE30F9-E15C-4EE0-98FD-0EBAA38A5222

P356

S12975-012-0149-X

P1433

Translational stroke research

P1476

Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.

@en

P2093

J Marc Simard

http://www.w3.org/2001/XMLSchema#string

Natalia Tsymbalyuk

http://www.w3.org/2001/XMLSchema#string

Oksana Voloshyn

http://www.w3.org/2001/XMLSchema#string

Ryan Lee

http://www.w3.org/2001/XMLSchema#string

Seung Kyoon Woo

http://www.w3.org/2001/XMLSchema#string

Svetlana Ivanova

http://www.w3.org/2001/XMLSchema#string

Vladimir Yurovsky

http://www.w3.org/2001/XMLSchema#string

Volodymyr Gerzanich

http://www.w3.org/2001/XMLSchema#string

P2860

Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke

Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage

Update of the stroke therapy academic industry roundtable preclinical recommendations

Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke.

Evaluation of MCAO stroke models in normotensive rats: standardized neocortical infarction by the 3VO technique.

Sequential activation of hypoxia-inducible factor 1 and specificity protein 1 is required for hypoxia-induced transcriptional stimulation of Abcc8.

Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury.

Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke.

Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.

Extension of the thrombolytic time window with minocycline in experimental stroke.

P2888

s12975-012-0149-x

P304

286-295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12975-012-0149-X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227180426

http://www.w3.org/2001/XMLSchema#string

P698

22707989

http://www.w3.org/2001/XMLSchema#string

P932

3362710

http://www.w3.org/2001/XMLSchema#string